This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

Treatment decisions in new era of individualized therapy for metastatic hormone-sensitive prostate cancer

prostate cancer
Prostate cancer cells. Credit: NIH Image Gallery

Oncologists have traditionally prescribed androgen deprivation therapy (ADT) alone for patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Now, there are many possible treatment options. Clinical trials have shown that more aggressive up-front treatment with a range of combination therapies improves outcomes. This shows how Dana-Farber Cancer Institute oncologists interpreted the evidence from these trials and applied it to an individual patient with mHSPC.

The researchers recommend aggressive up-front treatment with triplet therapy (ADT, an androgen-receptor pathway inhibitor, and chemotherapy) for who can tolerate chemotherapy, and especially for patients with high-volume disease. For patients with low-volume disease, they recommend adding radiation therapy if feasible.

The researchers also recommend the use of PSMA-PET scans to find metastases, evaluate treatment response, and identify potential sites for radiation.

Choosing a treatment approach requires interpretation of the results of many trials and the consideration of multiple factors unique to each patient. This case study provides that interpretation and gives evidence-based guidance for how to navigate decision-making for individual patients.

The research is published in the Journal of Clinical Oncology.

More information: Jeremiah Wala et al, Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer, Journal of Clinical Oncology (2023). DOI: 10.1200/JCO.23.00723

Journal information: Journal of Clinical Oncology
Citation: Treatment decisions in new era of individualized therapy for metastatic hormone-sensitive prostate cancer (2023, June 9) retrieved 21 June 2024 from https://medicalxpress.com/news/2023-06-treatment-decisions-era-individualized-therapy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

PROSPECT trial expands treatment options for patients with resectable rectal cancer

9 shares

Feedback to editors